A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder

Journal of Clinical Psychopharmacology

Volumn 24, Issue 5, 2004, Pages 488-496

  Rickels, Karl ^a   Mangano, Richard ^b   Khan, Arifulla ^c  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b PFIZER INC   (United States)

^c Northwest Clinical Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NORADRENALIN UPTAKE INHIBITOR; PLACEBO; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ADULT; AGED; ANOREXIA; ANORGASMIA; ANXIETY DISORDER; ARTICLE; CEREBELLUM INFARCTION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EJACULATION DISORDER; HUMAN; HYPERTENSION; IMPOTENCE; INSOMNIA; LIBIDO DISORDER; LIEBOWITZ SOCIAL ANXIETY SCALE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; NERVOUSNESS; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SEXUAL DYSFUNCTION; SHEEHAN DISABILITY INVENTORY; SIDE EFFECT; SOCIAL LIFE; SOCIAL PHOBIA; SOCIAL PHOBIA INVENTORY SCALE; SOMNOLENCE; SUSTAINED RELEASE PREPARATION; SWEATING; TREATMENT OUTCOME; VISUAL DISORDER; XEROSTOMIA;

ADULT; ANTI-ANXIETY AGENTS; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PERSONALITY ASSESSMENT; PERSONALITY INVENTORY; PHOBIC DISORDERS; SEROTONIN UPTAKE INHIBITORS; SOCIAL BEHAVIOR; TREATMENT OUTCOME;

EID: 4644343737     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000138764.31106.60     Document Type: Article

References (45)

1. Kessler RC, Stein MB, Berglund P. Social phobia subtypes in the National Comorbidity Survey. Am J Psychiatry. 1998;155(5):613-619.
2. Katzelnick DJ, Kobak KA, DeLeire T, et al. Impact of generalized social anxiety disorder in managed care. Am J Psychiatry. 2001;158(12): 1999-2007.
3. Lecrubier Y. Comorbidity in social anxiety disorder: impact on disease burden and management. J Clin Psychiatry. 1998;59(suppl 17):33-38.
4. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51(1):8-19.
5. Schneier FR, Johnson J, Hornig CD, et al. Social phobia. Comorbidity and morbidity in an epidemiologic sample. Arch Gen Psychiatry. 1992;49(4):282-288.
6. Weiller E, Bisserbe JC, Boyer P, et al. Social phobia in general health care: an unrecognised undertreated disabling disorder. Br J Psychiatry. 1996;168(2):169-174.
7. Lydiard RB. Social anxiety disorder: comorbidity and its implications. J Clin Psychiatry. 2001;62(suppl 1):17-23 discussion 24.
8. Davidson JR, Hughes DC, George LK, et al. The boundary of social phobia. Exploring the threshold. Arch Gen Psychiatry. 1994;51(12): 975-983.
9. Judd LL. Social phobia: a clinical overview. J Clin Psychiatry. 1994;55(suppl):5-9.
10. Pollack MH. Comorbidity, neurobiology, and pharmacotherapy of social anxiety disorder. J Clin Psychiatry. 2001;62(suppl 12):24-29.
11. Reich J, Yates W. A pilot study of treatment of social phobia with alprazolam. Am J Psychiatry. 1988;145(5):590-594.
12. Stein MB, Chartier MJ, Hazen AL, et al. Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation. J Clin Psychopharmacol. 1996;16(3):218-222.
13. Walker JR, Van Ameringen MA, Swinson R, et al. Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment. J Clin Psychopharmacol. 2000;20(6): 636-644.
14. Cuthbert BN. Social anxiety disorder: trends and translational research. Biol Psychiatry. 2002;51:4-10.
15. Coupland NJ. Social phobia: etiology, neurobiology, and treatment. J Clin Psychiatry. 2001;62(suppl 1):25-35.
16. Tse WS, Bond AJ. Difference in serotonergic and noradrenergic regulation of human social behaviours. Psychopharmacology (Berlin). 2002;159(2):216-221.
17. Knutson B, Wolkowitz OM, Cole SW, et al. Selective alteration of personality and social behavior by serotonergic intervention. Am J Psychiatry. 1998;155(3):373-379.
18. Tancer ME, Mailman RB, Stein MB, et al. Neuroendocrine responsivity to monoaminergic system probes in generalized social phobia. Anxiety. 1994;1(5):216-223.
19. Argyropoulos SV, Bell CJ, Nutt DJ. Brain function in social anxiety disorder. Psychiatr Clin North Am. 2001;24(4):707-722.
20. Van Ameringen MA, Lane RM, Walker JR, et al. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry. 2001;158(2):275-281.
21. van Vliet IM, den Boer JA, Westenberg HG. Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology (Berlin). 1994;115(1-2):128-134.
22. Stein MB, Fyer AJ, Davidson JR, et al. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry. 1999;156(5):756-760.
23. Stein MB, Liebowitz MR, Lydiard RB, et al. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA. 1998;280(8):708-713.
24. Gelenberg AJ, Lydiard RB, Rudolph RL, et al. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA. 2000;283(23):3082-3088.
25. Khan A, Upton GV, Rudolph RL, et al. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group. J Clin Psychopharmacol. 1998;18(1):19-25.
26. Silverstone PH, Salinas E. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. J Clin Psychiatry. 2001;62(7):523-529.
27. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178:234-241.
28. Rudolph RL, Feiger AD. A double-blind, randomized, placebo-controlled trial of once daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord. 1999;56:171-181.
29. Thase ME. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group. J Clin Psychiatry. 1997;58:393-398.
30. De Nayer A, Geerts S, Ruelens L, et al. Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety. Int J Neuropsychopharmacol. 2002;5:115-120.
31. Silverstone PH, Ravindran A. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group. J Clin Psychiatry. 1999;60(1):22-28.
32. Rudolph RL, Entsuah R, Chitra R. A meta-analysis of the effects of venlafaxine on anxiety associated with depression. J Clin Psychopharmacol. 1998;18:136-144.
33. Feighner JP, Entsuah AR, McPherson MK. Efficacy of once-daily venlafaxine extended release (ER) for symptoms of anxiety in depressed outpatients. J Affect Disord. 1998;47(1-3):55-62.
34. Rickels K, Pollack MH, Sheehan DV, et al. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry. 2000;157(6):968-974.
35. Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (XR) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry. 2001;179:15-22.
36. Davidson JR, DuPont RL, Hedges D, et al. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry. 1999;60(8):528-535.
37. Pollack MH, Worthington JJ 3rd, Otto MW, et al. Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull. 1996;32:667-670.
38. Yaryura-Tobias JA, Neziroglu FA. Venlafaxine in obsessive-compulsive disorder. Arch Gen Psychiatry. 1996;53:653-654.
39. Altamura AC, Piolo R, Vitto M, et al. Venlafaxine in social phobia: a study in selective serotonin reuptake inhibitor nonresponders. Int Clin Psychopharmacol. 1999;14:239-245.
40. Kelsey JE. Venlafaxine in social phobia. Psychopharmacol Bull. 1995;31:767-771.
41. Lara N, Baker GB, Archer SL, et al. Increased cholesterol levels during paroxetine administration in healthy men. J Clin Psychiatry. 2003;64:1455-1459.
42. Lydiard RB, Bobes J. Therapeutic advances: paroxetine for the treatment of social anxiety disorder. Depress Anxiety. 2000;11(3):99-104.
43. Shelton RC, Brown LL. Mechanisms of action in the treatment of anxiety. J Clin Psychiatry. 2001;62(suppl 12):10-15.
44. Allgulander C. Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatr Scand. 1999;100(3):193-198.
45. Ninan PT. The functional anatomy, neurochemistry, and pharmacology of anxiety. J Clin Psychiatry. 1999;60(suppl 22):12-17.